Adjudicore
A modular dossier workspace that binds one filing type to current authority, extracts source-linked candidates, exposes missing evidence, and produces a reviewer-approved package without claiming compliance or success.
Single-vertical products validate demand for structured regulatory dossiers, including a confirmed investor-visa plan generator priced per package. The research found no unified multi-vertical platform, but that absence is not automatically an advantage: an investor visa, medical prior authorization, operational-resilience incident, and workers' compensation chronology have different authorities, evidence, professional roles, privacy, filing routes, and consequences. Adjudicore must begin with one filing type and an independently governed module. It preserves source document, extracted candidate, authority and checklist version, required element, contradiction, missingness, reviewer decision, approved narrative, form field, signature authority, submission, receipt, adjudicator disposition, appeal, and correction. It never calls a generated package compliant, complete, examiner-ready, medically necessary, legally sufficient, or likely to succeed. The original stage verified no filing interface; human approval is mandatory but never decorative, and regulated professionals retain judgment and representation responsibility.
The regulated professional, specialist agency, legal or clinical operations team, or compliance service preparing repeated dossiers of one defined type.
A current cluster of regulated-professional products and a 2026 prior-authorization interface rule create present demand.
Regulated professionals and specialist operations teams have concrete repeated package workflows.
Recent vertical products show feasibility, while document assembly and checklists are established.
A confirmed paid single-vertical product, strong regulated-workflow growth, a clear professional buyer, and reusable evidence primitives support one-module-at-a-time delivery.
No interface was verified, horizontal scope multiplies legal and clinical risk, expert doctrine is expensive, human review limits self-service, and vertical competitors can defend their domains.
Discussion
No comments yet — be the first to weigh in.
